SCHEMBL3860330

SCHEMBL3860330

CC[C@@H](N(Cc1ccccc1)Cc1ccccc1)C(C)(C)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 2/20 0.42
TSHR P16473 3/20 0.41
ALDH1A1 P00352 2/20 0.41
CA12 O43570 1/20 0.41
CA9 Q16790 1/20 0.41
TP53 P04637 1/20 0.40
LMNA P02545 1/20 0.40
KMT2A Q03164 3/20 0.39
GAA P10253 1/20 0.39
NPBWR1 P48145 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
MCHR1 Q99705 1/20 0.39
AOC3 Q16853 1/20 0.38
MEN1 O00255 2/20 0.38
HTT P42858 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
SIGMAR1 Q99720 1/20 0.38
NR1H2 P55055 1/20 0.38
NR1H3 Q13133 1/20 0.38
MGLL Q99685 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3860326 1.00 RIPK1 (0.42) RIPK1TSHRALDH1A1CA12CA9
SCHEMBL13601327 1.00 RIPK1 (0.42) RIPK1TSHRALDH1A1CA12CA9
SCHEMBL90051 0.83 SIGMAR1 (0.40) RIPK1TSHRALDH1A1CA12CA9
SCHEMBL90384 0.83 SIGMAR1 (0.40) RIPK1TSHRALDH1A1CA12CA9
SCHEMBL6295805 0.80 TSHR (0.38) RIPK1TSHRALDH1A1CA12CA9
SCHEMBL15421785 0.78 SIGMAR1 (0.44) RIPK1TSHRALDH1A1KMT2AGAA
SCHEMBL15421788 0.78 SIGMAR1 (0.44) RIPK1TSHRALDH1A1KMT2AGAA
SCHEMBL24016959 0.75 TSHR (0.43) TSHRALDH1A1TP53LMNANPSR1
SCHEMBL1561608 0.74 RIPK1 (0.45) RIPK1ALDH1A1CA12CA9LMNA
SCHEMBL4432874 0.73 TSHR (0.46) TSHRALDH1A1CA12CA9TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8846696-B2 Purine derivatives CYCLACEL LIMITED (GB) 2014-09-30 US disclosed
US-20090325983-A1 NEW PURINE DERIVATIVES CYCLACEL LIMITED (GB) 2009-12-31 US disclosed
US-7582642-B2 4-{9-Isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-2-methyl-hexan-3-ol;antiproliferative agents; viricides; alopecia; strokes; central nervous system diorders; neurodegenerative diseases; antidiabetic agents; mitosis; cyclin dependent kinase inhibitors; protein kinase inhibitors CYCLACEL LIMITED (GB) 2009-09-01 US disclosed
EP-1529047-B1 NEW PURINE DERIVATIVES CYCLACEL LTD (GB) 2007-02-21 EP disclosed
EP-1529047-A2 NEW PURINE DERIVATIVES Cyclacel Limited (GB) 2005-05-11 EP disclosed
WO-2004016612-A2 NEW PURINE DERIVATIVES CYCLACEL LIMITED (GB) 2004-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325983-A1 NEW PURINE DERIVATIVES C5, CYC1, CCNH RIPK1 3336/4885TSHR 1257/4885ALDH1A1 1573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.